Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx32.htm |
| EX-31.2 - EXHIBIT 31.2 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx31x2.htm |
| EX-31.1 - EXHIBIT 31.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx31x1.htm |
| EX-21.1 - EXHIBIT 21.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx21x1.htm |
| EX-12.1 - EXHIBIT 12.1 - INTERCEPT PHARMACEUTICALS, INC. | v485049_exhx12x1.htm |
| EX-10.21 - EXHIBIT 10.21 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10-21.htm |
| EX-10.8 - EXHIBIT 10.8 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10-8.htm |
| EX-10.2.1 - EXHIBIT 10.2.1 - INTERCEPT PHARMACEUTICALS, INC. | tv485049_ex10x2x1.htm |
| 10-K - 10-K - INTERCEPT PHARMACEUTICALS, INC. | v485049_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Intercept Pharmaceuticals, Inc.:
We consent to the incorporation by reference in the registration statements on Form S-8 (No. 333 184810, No. 333-188064, and No. 333-206247) and Form S-3 (No. 333-194974) of Intercept Pharmaceuticals, Inc. of our reports dated February 28, 2018, with respect to the consolidated balance sheets of Intercept Pharmaceuticals, Inc. as of December 31, 2017 and 2016, and the related consolidated statements of operations, comprehensive loss, changes in stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2017, and the related notes (collectively, the “consolidated financial statements”), and the effectiveness of internal control over financial reporting as of December 31, 2017, which reports appear in the December 31, 2017 annual report on Form 10-K of Intercept Pharmaceuticals, Inc.
/s/ KPMG LLP
New York, New York
February 28, 2018